Почетна › Многи мијелом › Alabama
Kliničke studije za Многи мијелом u državi Alabama
22 studija za Многи мијелом traži učesnike na lokacijama u državi Alabama.
Gradovi u državi Alabama
Zvanični tekst studije (na engleskom)
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
- Infirmary Cancer Care, Mobile
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT06152575A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
- University of Alabama Birmingham, Birmingham
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT04634552A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
- Clearview Cancer Institute, Huntsville
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 30. 10. 2026. · NCT07284758A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
- University of Alabama at Birmingham, Birmingham
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 29. 10. 2026. · NCT06615479A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
- Gulf Health Hospitals, Inc. d/b/a Infirmary Cancer Care - Malbis, Daphne
- Gulf Health Hospitals, Inc. d/b/a Thomas Medical Center, Daphne
- Gulf Health Hospitals, Inc. d/b/a Infirmary Cancer Care - Fairhope, Fairhope
- и још 4
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 27. 10. 2026. · NCT05623020A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
- University of Alabama At Birmingham Hospital, Birmingham
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 26. 10. 2026. · NCT04973605A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
- Infirmary Health - Diagnostic & Medical Clinic (DMC), Mobile
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 13. 10. 2026. · NCT06980480AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
- Research Site, Birmingham
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 8. 10. 2026. · NCT05850234Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
- University of Alabama at Birmingham, Birmingham
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 6. 10. 2026. · NCT06297226A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- Alabama Oncology, Birmingham
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 25. 9. 2026. · NCT07518186A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
- University of Alabama at Birmingham Hospital, Birmingham
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 23. 9. 2026. · NCT07116616TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham
Тражи се учесникФаза 2
Узраст 12 и старији · Оба пола · Ажурирано 22. 9. 2026. · NCT02693535A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
- University of Alabama at Birmingham, Birmingham
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 2. 9. 2026. · NCT06988488A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
- University of Alabama at Birmingham, Birmingham
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 16. 7. 2026. · NCT06121843Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
- University of Alabama at Birmingham, Birmingham
Тражи се учесникФаза 2
Узраст 19 и старији · Оба пола · Ажурирано 4. 6. 2026. · NCT06974786A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
- GSK Investigational Site, Mobile
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 22. 4. 2026. · NCT06679101A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
- University of Alabama at Birmingham, Birmingham
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 18. 3. 2026. · NCT06153251Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)
- University of Alabama at Birmingham, Birmingham
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 31. 12. 2025. · NCT04991103Prehabilitation Feasibility Among Older Adults Undergoing Transplantation
- Kirklin Clinic of UAB Hospital, Birmingham
Тражи се учесник
Узраст 60 и старији · Оба пола · Ажурирано 24. 12. 2025. · NCT05642884Cancer and Aging Resilience Evaluation in Older Adults With Hematologic Malignancies: The CARE-Heme Registry
- Kirklin Clinic of UAB Hospital, Birmingham
Тражи се учесникОпсервациона студија
Узраст 50 и старији · Оба пола · Ажурирано 8. 12. 2025. · NCT05556928CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
- University of Alabama at Birmingham, Birmingham
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 25. 9. 2025. · NCT05722418A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
- UAB Comprehensive Cancer Center, Birmingham
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 5. 9. 2025. · NCT05372354Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.